A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes

Osteopathic Medicine and Primary Care

Volumn 1, Issue , 2007, Pages

  Edelman, Steven ^a   Dailey, George ^b   Flood, Thomas ^c   Kuritzky, Louis ^d   Renda, Susan ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

^c Georgia Center for Diabetes   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e Clinical Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250848999     PISSN: None     EISSN: 17504732     Source Type: Journal    
DOI: 10.1186/1750-4732-1-9     Document Type: Review

References (44)

1. Centers for Disease Control and Prevention National diabetes fact sheet: United States, 2005: General information 2005 http://www.cdc.gov/ diabetes/pubs/pdf/ndfs_2005.pdf
2. American Association of Clinical Endocrinologists The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update Endocr Pract 2002 8 suppl 1 40-82 15251848
3. American Diabetes Association Standards of medical care in diabetes--2007 Diabetes Care 2007 30 suppl 1 S4-S41 10.2337/dc07-S004 17192377
4. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study BMJ 2000 321 405-412 27454 10938048 10.1136/ bmj.321.7258.405
5. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853 10.1016/S0140-6736(05)61359-1 9742976
6. Riddle MC Rosenstock J Gerich J on behalf of the Insulin Glargine 4002 Study Investigators The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003 26 3080-3086 10.2337/diacare.26.11.3080 14578243
7. Saydah SH Fradkin J Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 2004 291 335-342 10.1001/jama.291.3.335 14734596
8. Polonsky WH Jackson RA What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes Clin Diabetes 2004 22 147-150 http://clinical.diabetesjournals.org/cgi/ content/full/22/3/147 10.2337/diaclin.22.3.147
9. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group Diabetes 1995 44 1249-1258 10.2337/diabetes.44.11.1249 7589820
10. Turner RC Cull CA Frighi V Holman RR for the UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999 281 2005-2012 10.1001/jama.281.21.2005 10359389
11. Wright A Burden ACF Paisey RB Cull CA Holman RR for the UK Prospective Diabetes Study Group Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) Diabetes Care 2002 25 330-336 10.2337/diacare.25.2.330 11815505
12. American Association of Clinical Endocrinologists Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement, February 2, 2005 2005 http://www.aace.com/pub/pdf/guidelines/ OutpatientImplementationPositionStatement.pdf
13. Leahy JL Intensive insulin therapy in type 1 diabetes mellitus Insulin Therapy New York, NY: Marcel Dekker, Inc. Leahy JL and Cefalu WT 2002 87-112
14. DeWitt DE Hirsch IB Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review JAMA 2003 289 2254-2264 10.1001/ jama.289.17.2265 12734137
15. Gerich JE Clinical significance, pathogenesis, and management of postprandial hyperglycemia Arch Intern Med 2003 163 1306-1316 10.1001/ archinte.163.11.1306 12796066
16. Monnier L Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest 2000 30 suppl 2 3-11 10975048
17. Metabolic Pulse Web site. How to initiate basal-prandial insulin therapy: A reference guide for the primary care clinician 2007 http://www.metabolicpulse.org/IntActivities.do
18. Khaw KT Wareham N Luben R Bingham S Oakes S Welch A Day N Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 2001 322 15-18 26599 11141143 10.1136/bmj.322.7277.15
19. Khaw KT Wareham N Bingham S Luben R Welch A Day N Association of hemoglobin A1C with cardiovascular disease and mortality in adults: The European Prospective Investigation into Cancer in Norfolk Ann Intern Med 2004 141 413-420 15381514
20. Bonora E Muggeo M Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: The epidemiological evidence Diabetologia 2001 44 2107-2114 10.1007/s001250100020 11793012
21. Coutinho M Gerstein HC Wang Y Yusuf S The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 1999 22 233-240 10.2337/diacare.22.2.233 10333939
22. Monnier L Lapinski H Colette C Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c Diabetes Care 2003 26 881-885 10.2337/diacare.26.3.881 12610053
23. Etgen GJ Oldham BA Johnson WT Broderick CL Montrose CR Brozinick JT Misener EA Bean JS Bensch WR Brooks DA Shuker AJ Rito CJ McCarthy JR Ardecky RJ Tyhonas JS Dana SL Bilakovics JM Paterniti JR Jr. Ogilvie KM Liu S Kauffman RF A tailored therapy for the metabolic syndrome: The dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models Diabetes 2002 51 1083-1087 10.2337/diabetes.51.4.1083 11916929
24. Hirsch IB Optimal initiation of insulin in type 2 diabetes Medscape General Medicine 2005 7 16614671
25. Naik RG Palmer JP Latent autoimmune diabetes in adults (LADA) Rev Endocr Metab Disord 2003 4 233-241 10.1023/A:1025148211587 14501174
26. Pozzilli P Di Mario U Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): Definition, characterization, and potential prevention Diabetes Care 2001 24 1460-1467 10.2337/diacare.24.8.1460 11473087
27. Nabhan F Emanuele MA Emanuele N Latent autoimmune diabetes of adulthood: unique features that distinguish it from types 1 and 2 Postgrad Med 2005 117 7-12 15782668
28. Cryer PE Davis SN Shamoon H Hypoglycemia in diabetes Diabetes Care 2003 26 1902-1912 10.2337/diacare.26.6.1902 12766131
29. Hermansen K Davies M Derezinski T Martinez Ravn G Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006 29 1269-1274 10.2337/dc05-1365 16732007
30. Apidra [package insert] Kansas City, Mo: Aventis Pharmaceuticals Inc 2005 http://products.sanofi-aventis.us/apidra/apidra.html
31. Owens DR Zinman B Bolli GB Insulins today and beyond Lancet 2001 358 739-746 10.1016/S0140-6736(01)05842-1 11551598
32. Exubera [package insert] New York, NY: Pfizer Inc. 2007 http://www.pfizer.com/pfizer/download/uspi_exubera.pdf
33. Byetta [package insert] San Diego, Calif: Amylin Pharmaceuticals, Inc. 2007 http://pi.lilly.com/us/byetta-pi.pdf
34. Edelman SV Incretins: What does the future hold? Diabetes Technol Ther 2005 7 809-812 10.1089/dia.2005.7.809 16241889
35. Edelman SV Weyer C Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second beta-cell hormone Diabetes Technol Ther 2002 4 175-189 10.1089/ 15209150260007390 12079621
36. Rašlová K Bogoev M Raz I Leth G Gall MA Hâncu N Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 2004 66 193-201 10.1016/ j.diabres.2004.03.003 15533587
37. Davies M Storms F Shutler S Bianchi-Biscay M Gomis R Study Group AT.LANTUS trial investigating treatment algorithms for insulin glargine (LANTUS): Results of the type 2 study [abstract 1980-PO] Diabetes 2004 53 suppl 2 A473
38. Tanenberg R Zisman A Stewart J Glycemia optimization treatment (GOT): glycemic control and rate of severe hypoglycemia for five different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM) [abstract 567-P] Diabetes 2006 55 (suppl 1) A135
39. Rohlfing CL Wiedmeyer HM Little RR England JD Tennill A Goldstein DE Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial Diabetes Care 2002 25 275-278 10.2337/diacare.25.2.275 11815495
40. US Food and Drug Administration New device approval: DexCom STS Continuous Glucose Monitoring System - P050012 2006 http://www.fda.gov/ cdrh/mda/docs/p050012.html
41. Cefalu WT Rationale for and strategies to achieve glycemic control Insulin Therapy New York, NY: Marcel Dekker Inc. Leahy JL and Cefalu WT 2002 1-11
42. Campbell RK White JR Jr. Insulin therapy in type 2 diabetes J Am Pharm Assoc (Wash) 2002 42 602-611 10.1331/108658002763029580 12150359
43. Ahmann AJ Riddle MC Insulin therapy in type 2 diabetes mellitus Insulin Therapy New York, NY: Marcel Dekker, Inc. Leahy JL and Cefalu WT 2002 113-124
44. Plank J Bodenlenz M Sinner F Magnes C Gorzer E Regittnig W Endahl LA Draeger E Zdravkovic M Pieber TR A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005 28 1107-1112 10.2337/diacare.28.5.1107 15855574